Description
EXERCISE OPTION YEAR 4, EFFECTIVE MAY 1, 2026 TO APRIL 30, 2027 FOR PREDNISOLONE ACETATE 1% OPHTHALMIC SUSPENSION WITH GREENSTONE LLC.
Base award description: NEW AWARD FOR PREDNISOLONE ACETATE 1% OPHTHALMIC SUSPENSION WITH GREENSTONE LLC. PERIOD OF PERFORMANCE IS MAY 1, 2022 TO APRIL 30, 2023 WITH FOUR ONE-YEAR OPTIONS.
First action · last action
2021-12-28 · 2026-03-09
Transactions
17
First transaction's obligation
$0
Base + all options value (sum of deltas)
$15,335,733
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
3
SDVOSB flag on record
No
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 17 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2021-12-28+$0= $0
- Mod P000012022-01-18+$0= $0
- Mod P000022022-12-01+$0= $0
- Mod P000032022-12-02+$0= $0
- Mod P000042022-12-15+$0= $0
- Mod P000052023-03-07+$0= $0
- Mod P000062023-04-20+$0= $0
- Mod P000072023-11-14+$0= $0
- Mod P000082023-11-30+$0= $0
- Mod P000092024-02-15+$0= $0
- Mod P000102024-03-06+$0= $0
- Mod P000112024-11-21+$0= $0
- Mod P000122024-12-19+$0= $0
- Mod P000132025-03-12+$0= $0
- Mod P000142025-12-08+$0= $0
- Mod P000152025-12-31+$0= $0
- Mod P000162026-03-09+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2021-12-28 | +$0 | $0 | NEW AWARD FOR PREDNISOLONE ACETATE 1% OPHTHALMIC SUSPENSION WITH GREENSTONE LLC. PERIOD OF PERFORMANCE IS MAY… |
| Mod P00001· ADD SUBCONTRACTING PLAN | 2022-01-18 | +$0 | $0 | INCORPORATION OF 2022 SMALL BUSINESS PLAN INTO CONTRACT 36E79722D0007 - PREDNISOLONE ACETATE 1% OPHTHALMIC SUS… |
| Mod P00002· OTHER ADMINISTRATIVE ACTION | 2022-12-01 | +$0 | $0 | ADMINISTRATIVE POC CHANGE. |
| Mod P00003· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2022-12-02 | +$0 | $0 | INCORPORATION OF 2023 FEDERAL CEILING PRICES. NO CHANGES TO THE NATIONAL CONTRACT PRICE. |
| Mod P00004· ADD SUBCONTRACTING PLAN | 2022-12-15 | +$0 | $0 | INCORPORATION OF 2023 SMALL BUSINESS SUBCONTRACTING PLAN INTO CONTRACT 36E79722D0007 - PREDNISOLONE ACETATE 1%… |
| Mod P00005· EXERCISE AN OPTION | 2023-03-07 | +$0 | $0 | EXERCISE OPTION YEAR 1 EFFECTIVE MAY 1, 2023 TO APRIL 30, 2024 FOR PREDNISOLONE ACETATE 1% OPHTHALMIC SUSPENSI… |
| Mod P00006· OTHER ADMINISTRATIVE ACTION | 2023-04-20 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE THE DRUG SUPPLY CHAIN SECURITY ACT (DSCSA) LANGUAGE INTO THE CONTRA… |
| Mod P00007· ADD SUBCONTRACTING PLAN | 2023-11-14 | +$0 | $0 | INCORPORATION OF 2024 SMALL BUSINESS SUBCONTRACTING PLAN INTO CONTRACT 36E79722D0007 - PREDNISOLONE ACETATE 1%… |
| Mod P00008· OTHER ADMINISTRATIVE ACTION | 2023-11-30 | +$0 | $0 | INCORPORATION OF 2024 FEDERAL CEILING PRICES INTO CONTRACT. THE AWARDED NATIONAL CONTRACT PRICES REMAIN UNCHAN… |
| Mod P00009· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2024-02-15 | +$0 | $0 | MODIFICATION FOR THE SUPPLEMENTAL CHANGES TO THE CRF PAYMENT SUBMITTAL AND SALES REPORTING REQUIREMENTS. |
| Mod P00010· EXERCISE AN OPTION | 2024-03-06 | +$0 | $0 | EXERCISE OPTION YEAR 2, EFFECTIVE MAY 1, 2024 TO APRIL 30, 2025 FOR PREDNISOLONE ACETATE 1% OPHTHALMIC SUSPENS… |
| Mod P00011· OTHER ADMINISTRATIVE ACTION | 2024-11-21 | +$0 | $0 | INCORPORATION OF 2025 FEDERAL CEILING PRICES INTO CONTRACT. THE AWARDED NATIONAL CONTRACT PRICES REMAIN UNCHAN… |
| Mod P00012· ADD SUBCONTRACTING PLAN | 2024-12-19 | +$0 | $0 | INCORPORATION OF MYLAN PHARMACEUTICALS 2025 SMALL BUSINESS SUBCONTRACTING PLAN FOR CONTRACT #36E79722D0007 - P… |
| Mod P00013· EXERCISE AN OPTION | 2025-03-12 | +$0 | $0 | EXERCISE OPTION YEAR 3, EFFECTIVE MAY 1, 2025 TO APRIL 30, 2026 FOR PREDNISOLONE ACETATE 1% OPHTHALMIC SUSPENS… |
| Mod P00014· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2025-12-08 | +$0 | $0 | INCORPORATION OF 2026 FEDERAL CEILING PRICES INTO EXISTING CONTRACT. THE AWARDED NATIONAL CONTRACT PRICES WERE… |
| Mod P00015· ADD SUBCONTRACTING PLAN | 2025-12-31 | +$0 | $0 | INCORPORATION OF MYLAN PHARMACEUTICALS 2026 SMALL BUSINESS SUBCONTRACTING PLAN FOR CONTRACT #36E79722D0007 - P… |
| Mod P00016· EXERCISE AN OPTION | 2026-03-09 | +$0 | $0 | EXERCISE OPTION YEAR 4, EFFECTIVE MAY 1, 2026 TO APRIL 30, 2027 FOR PREDNISOLONE ACETATE 1% OPHTHALMIC SUSPENS… |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI LYXPMLF136U4)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| V797D50559 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2016 |
| VA25514F3180 | 255-NETWORK CONTRACT OFFICE 15 · 6505 · DRUGS AND BIOLOGICALS | $64,641 | FY2014 |
| VA25514F2597 | 255-NETWORK CONTRACT OFFICE 15 · 6505 · DRUGS AND BIOLOGICALS | $1,017,565 | FY2014 |
| VA25514F2417 | 255-NETWORK CONTRACT OFFICE 15 · 6505 · DRUGS AND BIOLOGICALS | $7,977 | FY2014 |
| VA25514F2331 | 255-NETWORK CONTRACT OFFICE 15 · 6505 · DRUGS AND BIOLOGICALS | $62,999 | FY2014 |
| VA25514F2266 | 255-NETWORK CONTRACT OFFICE 15 · 6505 · DRUGS AND BIOLOGICALS | $8,957 | FY2014 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79722D0007_3600 · retrieved 2026-09-26.